Athira Pharma Inc. investors who sued the biotech company’s leaders urged a federal court to give final approval to a settlement that specifies several internal governance and oversight reforms following a research misconduct scandal.
The derivative suit settlement commits the board to maintain the changes for five years, shareholders Stephen Bushansky and Thomas Houlihan told the US District Court for the Western District of Washington in a July 3 filing.
The suit and a related class action stem from allegations that Athira’s former CEO, Leen Kawas, published research papers with altered images while completing graduate coursework—research that underlay the company’s ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.